Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michał Marzec, Qian Zhang, Ami Goradia, et al.
Proceedings of the National Academy of Sciences (2008) Vol. 105, Iss. 52, pp. 20852-20857
Open Access | Times Cited: 662

Showing 1-25 of 662 citing articles:

The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
Nature reviews. Cancer (2012) Vol. 12, Iss. 4, pp. 252-264
Open Access | Times Cited: 12390
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll
Cancer Cell (2015) Vol. 27, Iss. 4, pp. 450-461
Open Access | Times Cited: 3719
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian, Janis M. Taube, Robert A. Anders, et al.
Nature reviews. Cancer (2016) Vol. 16, Iss. 5, pp. 275-287
Open Access | Times Cited: 2394
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Janis M. Taube, Alison Klein, Julie R. Brahmer, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 19, pp. 5064-5074
Open Access | Times Cited: 2204
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou, Jedd D. Wolchok, Lieping Chen
Science Translational Medicine (2016) Vol. 8, Iss. 328
Open Access | Times Cited: 2122
The PD‐1 pathway in tolerance and autoimmunity
Loise M. Francisco, Peter T. Sage, Arlene H. Sharpe
Immunological Reviews (2010) Vol. 236, Iss. 1, pp. 219-242
Open Access | Times Cited: 2106
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel, Razelle Kurzrock
Molecular Cancer Therapeutics (2015) Vol. 14, Iss. 4, pp. 847-856
Closed Access | Times Cited: 2029
Regulation and Function of the PD-L1 Checkpoint
Chong Sun, Riccardo Mezzadra, Ton N. Schumacher
Immunity (2018) Vol. 48, Iss. 3, pp. 434-452
Open Access | Times Cited: 1813
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Ángel García-Díaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Cell Reports (2017) Vol. 19, Iss. 6, pp. 1189-1201
Open Access | Times Cited: 1530
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen, Xue Han
Journal of Clinical Investigation (2015) Vol. 125, Iss. 9, pp. 3384-3391
Open Access | Times Cited: 1297
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green, Stefano Monti, Scott J. Rodig, et al.
Blood (2010) Vol. 116, Iss. 17, pp. 3268-3277
Open Access | Times Cited: 1207
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
New England Journal of Medicine (2016) Vol. 375, Iss. 18, pp. 1767-1778
Open Access | Times Cited: 1173
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 18, pp. 4585-4593
Open Access | Times Cited: 1062
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen, Bjoern Chapuy, Jing Ouyang, et al.
Clinical Cancer Research (2013) Vol. 19, Iss. 13, pp. 3462-3473
Open Access | Times Cited: 800
Mechanisms Controlling PD-L1 Expression in Cancer
Jong‐Ho Cha, Li-Chuan Chan, Chia‐Wei Li, et al.
Molecular Cell (2019) Vol. 76, Iss. 3, pp. 359-370
Open Access | Times Cited: 736
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
Jiezhong Chen, Chen Chen Jiang, Lei Jin, et al.
Annals of Oncology (2015) Vol. 27, Iss. 3, pp. 409-416
Open Access | Times Cited: 687
Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
Kristin J. Lastwika, Willie Wilson, Qing Kay Li, et al.
Cancer Research (2015) Vol. 76, Iss. 2, pp. 227-238
Open Access | Times Cited: 685
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye, Zoaib Rasool
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 616
Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update
Joseph Clara, Cecilia Monge, Yingzi Yang, et al.
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 4, pp. 204-232
Closed Access | Times Cited: 614
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen, Wenfeng Fang, Jianhua Zhan, et al.
Journal of Thoracic Oncology (2015) Vol. 10, Iss. 6, pp. 910-923
Open Access | Times Cited: 607
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna S. Berghoff, Barbara Kiesel, Georg Widhalm, et al.
Neuro-Oncology (2014) Vol. 17, Iss. 8, pp. 1064-1075
Open Access | Times Cited: 525
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Kankana Bardhan, Theodora Anagnostou, Vassiliki A. Boussiotis
Frontiers in Immunology (2016) Vol. 7
Open Access | Times Cited: 511
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O’Donnell, Georgina V. Long, Richard A. Scolyer, et al.
Cancer Treatment Reviews (2016) Vol. 52, pp. 71-81
Closed Access | Times Cited: 502
A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects
Yuki Kagoya, Shinya Tanaka, Tingxi Guo, et al.
Nature Medicine (2018) Vol. 24, Iss. 3, pp. 352-359
Open Access | Times Cited: 439
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron M. Goodman, Sandip Pravin Patel, Razelle Kurzrock
Nature Reviews Clinical Oncology (2016) Vol. 14, Iss. 4, pp. 203-220
Closed Access | Times Cited: 416
Page 1 - Next Page

Scroll to top